美国食品药品监督管理局（FDA）已正式批准Rybrevant Faspro™（含Amivantamab与透明质酸酶-Lpuj）上市，该疗法成为目前唯一一款可实现每月一次给药频率的EGFR靶向治疗药物。这一突破性审批为特定非小细胞肺癌患者提供了更便捷的治疗选择，有望显著提升用药依从性与生活质量。
美国食品药品监督管理局（FDA）已正式批准Rybrevant Faspro™（含Amivantamab与透明质酸酶-Lpuj）上市，该疗法成为目前唯一一款可实现每月一次给药频率的EGFR靶向治疗药物。这一突破性审批为特定非小细胞肺癌患者提供了更便捷的治疗选择，有望显著提升用药依从性与生活质量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.